ABT-888 (Veliparib) in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
- Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
breast or ovarian cancer, but may include prostate or pancreatic cancer). Progressive disease after standard therapy OR no acceptable standard treatment options available.
Type of study:
- Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.
UPMC Cancer Center
Pittsburgh, Pennsylvania, 15232
Contact: Clinical Trials Office - UPMC Cancer Centers 412-647-8073
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.